{
    "clinical_study": {
        "@rank": "335",
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on April 08, 2020",
            "link_text": "Link to the current ClinicalTrials.gov record.",
            "url": "https://clinicaltrials.gov/show/NCT04261907"
        },
        "id_info": {
            "org_study_id": "ASC09F-CTP-ZY-01",
            "nct_id": "NCT04261907"
        },
        "brief_title": "Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection",
        "official_title": "A Randomized, Open-label, Multi-centre Clinical Trial Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Confirmed Cases of Pneumonia Caused by Novel Coronavirus Infection",
        "sponsors": {
            "lead_sponsor": {
                "agency": "First Affiliated Hospital of Zhejiang University",
                "agency_class": "Other"
            },
            "collaborator": {
                "agency": "Ascletis Pharmaceuticals Co., Ltd.",
                "agency_class": "Industry"
            }
        },
        "source": "First Affiliated Hospital of Zhejiang University",
        "oversight_info": {
            "has_dmc": "No",
            "is_fda_regulated_drug": "No",
            "is_fda_regulated_device": "No"
        },
        "brief_summary": {
            "textblock": "Base on Arbidol antiviral therapy,the investigators conduct a randomized, open-label trial to\n      evaluate and compare the safety and efficacy of ASC09 /ritonavir and lopinavir/ritonavir in\n      patients with 2019-nCoV pneumonia."
        },
        "overall_status": "Not yet recruiting",
        "start_date": {
            "@type": "Anticipated",
            "#text": "February 7, 2020"
        },
        "completion_date": {
            "@type": "Anticipated",
            "#text": "June 30, 2020"
        },
        "primary_completion_date": {
            "@type": "Anticipated",
            "#text": "May 31, 2020"
        },
        "phase": "N/A",
        "study_type": "Interventional",
        "has_expanded_access": "No",
        "study_design_info": {
            "allocation": "Randomized",
            "intervention_model": "Parallel Assignment",
            "primary_purpose": "Treatment",
            "masking": "None (Open Label)"
        },
        "primary_outcome": {
            "measure": "The incidence of composite adverse outcome",
            "time_frame": "14 days",
            "description": "Defined as(one of them) SPO2\u2264 93% without oxygen supplementation, PaO2/FiO2 \u2264 300mmHg or RR \u2265 30 breaths per."
        },
        "secondary_outcome": [
            {
                "measure": "Time to recovery",
                "time_frame": "14 days",
                "description": "Clinical recovery was defined as( one of them): sustained (48 hours) alleviation of illness based on symptom scores (fever, cough,diarrhea, myalgia, dyspnea) all being absent and no evidence for progression (newly-presented dyspnea, SpO2 decline \u22653%, respiratory rate \u2265 24 breaths per min without supplemental oxygen). Or undectable viral RNA."
            },
            {
                "measure": "Rate of no fever",
                "time_frame": "14 days"
            },
            {
                "measure": "Rate of no cough",
                "time_frame": "14 days"
            },
            {
                "measure": "Rate of no dyspnea",
                "time_frame": "14 days"
            },
            {
                "measure": "Rate of no requring supplemental oxygen",
                "time_frame": "14 days"
            },
            {
                "measure": "Rate of undectable viral RNA",
                "time_frame": "14 days"
            },
            {
                "measure": "Rate of mechanical ventilation",
                "time_frame": "14 days"
            },
            {
                "measure": "Rate of ICU admission",
                "time_frame": "14 days"
            },
            {
                "measure": "Time and rate of laboratory indicators related to disease improvement to return to normal",
                "time_frame": "14 days"
            }
        ],
        "number_of_arms": "2",
        "enrollment": {
            "@type": "Anticipated",
            "#text": "160"
        },
        "condition": "2019-nCoV",
        "arm_group": [
            {
                "arm_group_label": "ASC09/ritonavir group",
                "arm_group_type": "Experimental",
                "description": "ASC09/ritonavir (300mg/100mg tablet)+conventional standardized treatment"
            },
            {
                "arm_group_label": "lopinavir/ritonavir group",
                "arm_group_type": "Active Comparator",
                "description": "Lopinavir/ritonavir tablet (200mg / 50mg tablet)+conventional standardized treatment"
            }
        ],
        "intervention": [
            {
                "intervention_type": "Drug",
                "intervention_name": "ASC09/ritonavir group",
                "description": "ASC09/ritonavir(300mg/100mg tablet), one tablet each time, twice daily, for 14 days, +conventional standardized treatment",
                "arm_group_label": "ASC09/ritonavir group"
            },
            {
                "intervention_type": "Drug",
                "intervention_name": "lopinavir/ritonavir group",
                "description": "Lopinavir/ritonavir tablets(200mg / 50mg tablet), two tablets each time, twice daily, for 14 days, +conventional standardized treatment",
                "arm_group_label": "lopinavir/ritonavir group"
            }
        ],
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  1. Aged between 18 and 75 years, extremes included, male or female\n\n          -  2. Laboratory (RT-PCR) and clinical symptoms confirmed case of 2019-nCoV pneumonia,\n             according to the official guideline \"Pneumonia Diagnosis and Treatment Scheme for\n             Novel Coronavirus Infection (Trial Version 5)\"\n\n          -  3. Hospitalised with a new onset respiratory illness (\u22647 days since illness onset)\n\n          -  4. No family planning within six months, and agree to take effective contraceptive\n             measures throughout the study and for at least 30 days after the final study drug dose\n\n          -  5. Must agree not to enroll in another study of an investigational agent prior to\n             completion of Day 30 of study\n\n          -  6. Informed Consent Form (ICF) signed voluntarily\n\n        Exclusion Criteria:\n\n          -  1. Severe 2019-nCoV pneumonia met one of the following criteria: respiratory distress,\n             RR \u2265 30 times / min, or SaO2 / SpO2 \u2264 93% in resting state, or arterial partial\n             pressure of oxygen (PaO2) /concentration of oxygen (FiO2) \u2264 300mmHg (1mmHg = 0.133kpa)\n\n          -  2. Critical severe 2019-nCoV pneumonia met one of the following criteria: respiratory\n             failure and mechanical ventilation required, or shock, or combined with other organ\n             failure required ICU monitoring treatment\n\n          -  3. Severe liver disease (e.g. Child Pugh score \u2265 C, AST > 5 times upper limit)\n\n          -  4. Known allergic reaction to any of components of ASC09 / ritonavir compound tablets\n\n          -  5. Patients with definite contraindications in the label of ritonavir\n\n          -  6. Positive serum pregnancy test result for women with childbearing potential at\n             screening\n\n          -  7. Using HIV protease inhibitor drugs\n\n          -  8. Not suitable for the study, in the opinion of the Investigator (e.g. patient may be\n             transferred to another hospital during the study period, patient with multiple basic\n             diseases, etc.)"
            },
            "gender": "All",
            "minimum_age": "18 Years",
            "maximum_age": "75 Years",
            "healthy_volunteers": "No"
        },
        "overall_official": {
            "last_name": "Yunqing Qiu, Master",
            "role": "Principal Investigator",
            "affiliation": "First Affiliated Hospital of Zhejiang University"
        },
        "overall_contact": {
            "last_name": "Xiaowei Xu, Master",
            "phone": "+86 13605708066",
            "email": "xxw69@126.com"
        },
        "overall_contact_backup": {
            "last_name": "Jian Liu, Master",
            "phone": "+86 13958054006",
            "email": "lindaliu87@zju.edu.cn"
        },
        "verification_date": "February 2020",
        "study_first_submitted": "February 6, 2020",
        "study_first_submitted_qc": "February 6, 2020",
        "study_first_posted": {
            "@type": "Actual",
            "#text": "February 10, 2020"
        },
        "last_update_submitted": "February 6, 2020",
        "last_update_submitted_qc": "February 6, 2020",
        "last_update_posted": {
            "@type": "Actual",
            "#text": "February 10, 2020"
        },
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        },
        "condition_browse": {
            "mesh_term": [
                "Coronavirus Infections",
                "Severe Acute Respiratory Syndrome"
            ]
        },
        "intervention_browse": {
            "mesh_term": [
                "Ritonavir",
                "Lopinavir"
            ]
        },
        "patient_data": {
            "sharing_ipd": "No"
        }
    }
}